The study reported a cohort of patients achieving disease remission with significant reductions in SLE Disease Activity Index (SLEDAI) scores and normalization of complement factor levels after CD19 CAR-T cell treatment. This evidence concerns the gene CD19 and systemic lupus erythematosus.